Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study

Affiliations

• ¹ Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy.
• ² Venetian Institute of Molecular Medicine, Padua, Italy.
• ³ Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy.
• ⁴ Hematology Unit, Ca' Foncello Hospital, Treviso, Italy.
• ⁵ Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
• ⁶ Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore, University of Milan, Milan, Italy.
• ⁷ Hematology Institute, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
• ⁸ Hematology Unit, Careggi Hospital, University of Florence, Florence, Italy.
• ⁹ Division of Hematology, A.O. SS Antonio e Biagio and Cesare Arrigo, Alessandria, Italy.
• ¹⁰ Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS "G. Brotzu", Cagliari, Italy.
• ¹¹ Hematology Unit, Department of Hemato-Oncology, Annunziata Hospital, Cosenza, Italy.
• ¹² Hematology Section, Department of Medical Sciences, Azienda Ospedaliera-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy.
• ¹³ Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
• ¹⁴ Strategic Research Program on CLL, Vita-Salute University and IRCSS San Raffaele Hospital, Milan, Italy.
• ¹⁵ Hematology and Clinical Immunology Unit, University of Perugia, Perugia, Italy.
• ¹⁶ Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.